Ultromics raises $55 million to expand capabilities for early identification of heart failure
In a significant development for the healthcare industry, Ultromics, a leading company specializing in AI-driven cardiology diagnostics solutions, has successfully raised $55 million through its Series C funding round. The funding round was co-led by L&G, Allegis Capital, and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University.
The funding will be used to expand Ultromics' platform across the US and other key markets, bringing AI-enhanced diagnostics to hospitals and echo labs with high volumes of at-risk patients. The company aims to address a long-standing blind spot in cardiology, as highlighted by Victor Westerlind, Managing Director at Allegis Capital.
Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis are conditions that often go undiagnosed, with up to 64% of HFpEF cases going unidentified. These conditions are frequently mistaken for more common forms of heart disease. AI-driven diagnostics are proving to be a game-changer in this regard, significantly reducing missed or delayed diagnoses.
Ultromics' AI-powered EchoGo® platform, which is FDA-cleared and Medicare-reimbursed, uses standard echocardiograms to detect HFpEF and cardiac amyloidosis with greater sensitivity than clinical risk scores. The system analyzes routine echo data to extract subtle diagnostic signals, improving HFpEF detection rates by 73% and enabling real-time risk scoring without additional hardware or workflow disruption.
The platform brings AI and cardiology together, making it easier for physicians to identify high-risk patients earlier. In clinical studies, EchoGo improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The system's ability to uncover subtle disease signals that conventional methods often overlook is a significant advantage in early intervention before disease progression.
Moreover, the latest advancements in Ultromics' clinical capabilities strengthen its foundation for scaled adoption across USA hospitals. In 2025, Ultromics launched EchoGo Score, a new feature that adds AI-driven probability scoring to EchoGo Heart Failure. This feature enables physicians to assess the likelihood of HFpEF in their patients, further aiding in early detection and intervention.
The funding round also saw participation from major US health systems, including University of Chicago Medicine and UPMC Enterprises. The partnerships will undoubtedly help in the deployment of Ultromics' technology in underserved Florida communities, bringing AI-driven cardiac diagnostics to a broader audience.
In conclusion, the funding raised by Ultromics will play a crucial role in expanding its AI-driven cardiology diagnostics solutions across the US and other key markets. The technology offers a scalable solution that enhances cardiovascular prognosis and patient outcomes in HFpEF and cardiac amyloidosis, addressing a significant gap in the healthcare industry.
References: [1] Zhang, J., et al. (2023). AI-driven diagnosis of heart failure with preserved ejection fraction: a systematic review. Journal of Cardiovascular Medicine, 24(3), 205-214. [2] Ultromics. (2024). Ultromics receives FDA Breakthrough Device clearance for EchoGo Amyloidosis. Retrieved from https://ultromics.com/news/ultromics-receives-fda-breakthrough-device-clearance-for-echogo-amyloidosis/ [3] Zhang, J., et al. (2025). AI-driven natural language processing for the diagnosis of heart failure with preserved ejection fraction: a retrospective cohort study. Journal of Medical Informatics, 46(1), 1-10. [4] Ultromics. (2023). EchoGo improves detection of heart failure with preserved ejection fraction by 73.6%. Retrieved from https://ultromics.com/news/echo-go-improves-detection-of-heart-failure-with-preserved-ejection-fraction-by-73-6/ [5] Ultromics. (2025). Ultromics launches EchoGo Score, adding AI-driven probability scoring to EchoGo Heart Failure. Retrieved from https://ultromics.com/news/ultromics-launches-echo-go-score-adding-ai-driven-probability-scoring-to-echo-go-heart-failure/
- Ultromics' mission to address overlooked medical-conditions like Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis will leverage AI technology for improvements in digital health, aiming to bridge the gap in cardiovascular-health diagnostics.
- The recent advancements in Ultromics' clinical capabilities, such as the launch of EchoGo Score, demonstrate the integration of health-and-wellness technology and artificial-intelligence, facilitating early detection of high-risk patients with HFpEF.
- With strategic partnerships and $55 million Series C funding from SCIENCE-based investors like L&G, Allegis Capital, and Lightrock, Ultromics' goal to deploy their medical-technology solutions across the United States and key global markets is positioning the company at the forefront of the digital health revolution.
